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RESULTS: A total fo 3,975 women with HSDD and 11,925 controls were identiﬁed 
for the 12-month follow-up period. Women with HSDD had signiﬁcantly fewer 
inpatient admissions (0.07 vs. 0.09) and more general outpatient medical (29.26 vs. 
19.13), behavioral health ofﬁce (1.82 vs. 0.71) and more radiology (3.10 vs. 2.30) 
visits in the 12-month follow-up period versus controls. Cost differences were also 
observed among women with HSDD relative to their controls—with greater costs for 
general outpatient medical ($3427), behavioral health ofﬁce ($197) and radiology 
($515) visits in the 12-month follow-up period among women with HSDD than for 
controls (general outpatient medical visits: $2334; behavioral health ofﬁce visits: $77; 
radiology visits: $377; all p < 0.001). Differences in utilization and costs persisted in 
the 24 and 36-month follow-up periods. CONCLUSIONS: Women with HSDD have 
higher ‘downstream’ costs than women without any sexual dysfunction. The develop-
ment of treatment modalities that effectively control HSDD symptoms may present 
an opportunity to better manage health care utilization and costs in this population.
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OBJECTIVES: To determine the cost-effectiveness of HP-HMG (menotropin, 
MENOPUR®) compared to rFSH (follitropin alpha, GONAL-F®), in producing live 
births in the ovulatory patient participating in an ART Program. METHODS: A previ-
ously validated and published European Markov model was adapted to the Canadian 
setting to estimate the incremental cost per additional live birth gained for HP-HMG 
compared to rFSH, projected over three treatment cycles. These cycles included an 
initial fresh cycle then two additional cycles, as needed, of either fresh or cryoperserved 
embryos. Live birth rates were derived from a published meta-analysis comparing 
HP-HMG menotropin to rFSH follitropin alpha. Factors such as discontinuation, 
ooctye fertilization and pregnancy rates were derived from the published literature. 
All clinical outcomes were validated against published Canadian ART registry data 
and through clinical expert review. The analysis focused on direct medical costs only 
from the perspective of a provincial public health care system (Quebec). Cost data 
were obtained from a variety of sources including published references, provincial 
health care sources and expert opinion. All costs were reported as 2009 Canadian 
Dollars ($CAD). Given the short time-horizon discounting was not applied. Multiple 
sensitivity analyses were undertaken to test the robustness of the model to variations 
in key parameters including the cost and relative outcomes of comparators. RESULTS: 
The base case analysis indicates that HP-HMG results in a total cost per patient of 
$CAD 11,742 over 3 cycles compared to $CAD 13,202 for rFSH. Further, treatment 
with HP-HMG results in more live births than rFSH with 0.485 versus 0.421, respec-
tively. Thus, treatment with HP-HMG is dominant relative to rFSH (less costly and 
more effective). Results were robust over multiple sensitivity analyses. CONCLU-
SIONS: Treatment with HP-HMG (MENOPUR) is cost-effective compared to rFSH 
(GONAL-F), providing a greater number of live births at a lower cost to the public 
health care system.
PIH15
COST EFFECTIVENESS ANALYSIS OF FDA APPROVED ORAL 
EMERGENCY CONTRACEPTIVES
Patel HK, Patel J, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: Unintended pregnancies, a health problem with signiﬁcant economic 
burden on US could be avoided by use of FDA approved oral emergency contraceptives 
(ECPs) namely Plan B one-step (one pill regimen) and Next choice (two pill regimen). 
The objective of this study was to conduct a head-to-head comparison of these oral 
ECPs. METHODS: A cost effectiveness (CE) decision tree model was developed using 
data from published randomized controlled trails (effectiveness values) and primary 
data collection. Cost of each drug was obtained by taking an average of the price of 
drug from 5 large chain pharmacies. Outcomes considered were no pregnancy, birth, 
induced abortion, spontaneous abortion or ectopic pregnancy. Cost and probabilities 
of each outcome was derived from past literature and included only the direct costs. 
All adverse events with a probability of more than 5% and the direct cost associated 
with treating each of those adverse events were considered. These adverse events gener-
ally last for duration of one week, which was used to derive cost information for 
adverse events. The analysis involved only a onetime cost of taking an emergency 
contraceptive. Results were validated using one way and two way sensitivity analyses 
by varying the cost and effectiveness by a range of 25% each. RESULTS: The brand 
name drug Plan B one-step as opposed to the generic counterpart available, Next 
Choice, emerged as the cost effective option to avoid unintended pregnancy. The cost 
of treatment with Plan B one-step was $859 as opposed to $1075 for Next Choice. 
Two-way sensitivity analyses were robust and indicated that treatment with Plan B 
one-step completely dominated Next Choice. CONCLUSIONS: Plan B one-step; a one 
pill emergency contraceptive drug, with a higher retail price was found to be more 
cost effective than Next Choice.
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OBJECTIVES: To determine the cost-effectiveness of different treatment options and 
optimal number of treatments for symptomatic uterine ﬁbroids among premenopausal 
women who would prefer to retain uterus. METHODS: A Markov model with a 
1-year cycle length was developed. Women entered the model at diagnosis with 
symptomatic ﬁbroids and were followed to menopause or age 60 years, when all 
women were assumed to reach menopause. Treatment options included watchful 
waiting, myomectomy, and one-time, 6-month use of gonadotropin-releasing hormone 
(GnRH). In the model, women treated unsuccessfully or whose symptoms recurred 
could undergo up to three additional treatments or stop treatment at any point. Data 
on treatment efﬁcacy, quality-of-life, and medical costs (2007 US$) were from pub-
lished studies. For myomectomy, the probabilities of repeat procedures and of emer-
gency hysterectomy were from a large US claims database analysis. Age-speciﬁc rates 
for pregnancy and menopause were based on US data. Total costs and quality-adjusted 
life years (QALYs), discounted annually at 3%, were calculated for each treatment 
strategy for women diagnosed at different ages. Incremental cost-effectiveness ratios 
(ICERs) were calculated and an efﬁciency frontier was plotted. RESULTS: Base-case 
results for women diagnosed at age 20 years showed treatment strategies including 
GnRH were dominant compared with treatment strategies including myomectomy 
only and were cost-effective compared with watchful waiting (ICER range: $3789-
$7456 per QALY gained). Additional procedures for women whose symptoms 
recurred led to increased medical costs and QALYs, resulting in an incremental cost 
per QALY gained of $13,307, $15,433, and $17,555 for the second, third, and fourth 
myomectomy, respectively. Results were sensitive to age at diagnosis, number of treat-
ments, and the disutility associated with a woman losing her uterus via emergency 
hysterectomy. CONCLUSIONS: This model is the ﬁrst to assess the cost-effectiveness 
and optimal number of treatments speciﬁcally for a woman with ﬁbroids seeking to 
retain her uterus.
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OBJECTIVES: The objective of this study was to evaluate the cost and clinical out-
comes of single versus double embryo transfer using cleavage-stage or blastocyst-stage 
embryo in assisted reproduction. METHODS: Markov model was designed to simu-
late outcomes of: 1) single-(cleavage-stage) embryo transfer (SET); 2) double-embryo 
transfer (DET); 3) single-blastocyst transfer (SBT); and 4) double-blastocyst transfer 
(DBT). Model inputs were estimated from literature and cost analysis was conducted 
from health care provider’s perspective. RESULTS: The base-case analysis showed 
that DBT was the most costly (US$5173) and effective strategy (birth rate = 0.311) 
in fresh cycle. The cumulative cost and birth rate of SET were the highest in all cycles. 
Monte Carlo 10,000 simulations showed that the probability of DBT to be cost-
effective in fresh cycle was the highest when willingness-to-pay (WTP) per live birth 
was ≥US$85,000. In all cycles, the probability of SET to be cost-effective was the 
highest when WTP was ≥US$50,000. CONCLUSIONS: CONCLUSIONS DBT 
appears to be the most costly and most effective strategy in fresh cycle whereas SET 
seems to have the highest cumulative cost and live birth rate.
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OBJECTIVES: To estimate the incremental costs of necrotizing enterocolitis (NEC) 
among extremely preterm infants (GA < 28 weeks) and to evaluate the cost-effective-
ness of an exclusively human-milk based diet (fortiﬁed with Prolacta + HMFTM) vis-
à-vis human-milk fortiﬁed with a bovine-milk based supplement in the prevention of 
NEC. METHODS: California OSHPD 2007 hospital discharges database was used 
to estimate the incremental costs of NEC and surgical NEC among all preterm infants. 
Costs were adjusted for confounding by demographics, gestation age, mortality and 
comorbidities. Expected medical costs of NEC among extremely preterm infants fed 
either exclusively human-milk based diet or human-milk fortiﬁed with bovine-milk 
based fortiﬁer were calculated based on ﬁndings from a randomized controlled trial 
comparing neonatal outcomes of extremely preterm infants fed either of these diets. 
RESULTS: The adjusted incremental costs of NEC and surgical NEC among extremely 
preterm infants in 2009 US$ were 69,185 and $198,490 respectively per infant (p < 
0.0001). Expected medical costs of NEC were higher among infants fed human-milk 
fortiﬁed with bovine-milk based supplement resulting in net savings of $16,875 per 
infant for infants fed exclusively human-milk based diet (p < 0.0001). The societal 
costs savings for the US population of premature infants is estimated to be US$ 
